17.11.2014 - Pfizer is going to invest $ 850 million in new drug
American corporation Pfizer and German Merck KGaA, agreed to cooperate on the development of anti-tumor drug. As a result, Merck KGaA will receive $ 850 million for the development and preparation for sale anti-PD-L1, and can later get another $ 2 billion. The deal is the biggest in the pharmaceutical business. Given the ambitious plans of the two companies on a background of stable sales and earnings growth, we recommend to keep shares of these companies in the long term portfolio with the growth potential of up to 35% for the year.